



(51) International Patent Classification:

A61K 39/12 (2006.01) A61K 9/00 (2006.01)

A61K 47/26 (2006.01) A61K 9/14 (2006.01)

(21) International Application Number:

PCT/US2018/063541

(22) International Filing Date:

03 December 2018 (03.12.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/595,842 07 December 2017 (07.12.2017) US

(71) Applicant: MERCK SHARP & DOHME CORP.

[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): RYAN, Michael, S. [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). MARTIN, Sherrie-Ann, P. [US/US]; 770 Sumney-

town Pike, West Point, Pennsylvania 19486 (US). JONES, Morrisa [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). STANBRO, Justin [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). BHAMBHANI, Akhilesh [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). BLUE, Jeffrey Thomas [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). PIXLEY, Heidi Joanne [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). GREEN-TREXLER, Erin, J. [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). ISOPI, Lynne Ann [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US).

(74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS




FIG. 1

(57) Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.



HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*